SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2023 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “I am very pleased with the progress of our projects in 2023. We are strengthened in our belief that our projects have the potential to…
SECOND QUARTER IN BRIEF Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19) Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26) Positive safety and tolerability in…
Active Biotech’s Annual Report 2022 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.comHans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com About Active Biotech Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is…
SECOND QUARTER IN BRIEF Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26) FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18) Successful completion…
Active Biotech’s Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO,…
Active Biotech’s Annual Report 2019 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Download as PDF Lund, April 23, 2020 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46…
PRESS RELEASE Active Biotech’s Annual Report 2018 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Download as PDF Lund, April 26, 2019 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel.…
PRESS RELEASE Active Biotech’s Annual Report 2017 is now available för download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Lund, April 23, 2018 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46 192044…
